Drug intelligence / Profile preview

anti-FGFR4 Nb2 CAR-T

Development stage: Preclinical
Lead developer: National Cancer Institute
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Gene Therapies
Administration: Intravenous

Overview

anti-FGFR4 Nb2 CAR-T is a nanobody-based Chimeric Antigen Receptor T (CAR-T) cell therapy under development for the treatment of hepatocellular carcinoma (HCC). This therapy utilizes nanobodies (Nb2) to specifically target Fibroblast Growth Factor Receptor 4 (FGFR4) expressed on HCC cells, aiming to overcome challenges such as the suppressive tumor microenvironment and antigen heterogeneity often encountered in HCC CAR-T treatments.

Targets

FGFR4 (Fibroblast growth factor receptor 4)

Beyond the preview

Go deeper on anti-FGFR4 Nb2 CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-FGFR4 Nb2 CAR-T.

Explore the full profile